Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Lilly’s Cymbalta Wins FDA Approval For Major Depression Maintenance Therapy

This article was originally published in The Pink Sheet Daily

Executive Summary

The battle with Wyeth’s competing SNRI Effexor XR for new indications continues; Cymbalta could see an indication for fibromyalgia in 2008.

You may also be interested in...



Lilly Wins Fibromyalgia Management Indication For Cymbalta

The blockbuster SNRI is second into the fibromyalgia space, following Pfizer’s Lyrica.

Lilly Wins Fibromyalgia Management Indication For Cymbalta

The blockbuster SNRI is second into the fibromyalgia space, following Pfizer’s Lyrica.

Forest Hopeful No More Trials Needed For Milnacipran Fibromyalgia Filing

Priority review could bring the drug to market in June, at the same time competitor Lilly’s Cymbalta may be approved for the indication.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS065439

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel